Skip to content

Study · In vitro (cell-free) · 2021

1 result

Synthesis, Pharmacological, and Biological Evaluation of 2-Furoyl-Based MIF-1 Peptidomimetics and the Development of a General-Purpose Model for Allosteric Modulators (ALLOPTML).

Sampaio-Dias IE, Rodríguez-Borges JE, Yáñez-Pérez V, Arrasate S, Llorente J, Brea JM, Bediaga H, Viña D, Loza MI, Caamaño O, García-Mera X, González-Díaz H

ACS chemical neuroscience21 Dec 2020Cited by 16 (Europe PMC)

PMID33347281 (opens in a new tab)DOI10.1021/acschemneuro.0c00687 (opens in a new tab)PepBankPUB-33347281
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Activity measurement

    In D2 receptor assays, MIF‑1 increased maximal tritiated NPA response by 18 ± 9% at 10 pM, comparable to 6a.

    In plain wordsIn lab tests, MIF‑1 increased the maximum NPA response, with an effect comparable to compound 6a.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseMaximal NPA response
    Study

    n: not reported in source

    D2 receptor binding assay
    Comparator
    2-furoyl-l-leucylglycinamide (6a) at 10 pM
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    10 pMAs given in this study.

    Measurements

    Maximal NPA response increase
    18%
    MIF-1 at 10 pM

    Source sentences

    Summary
    In this series, 2-furoyl-l-leucylglycinamide (6a) produced a statistically significant increase in the maximal [3H]-NPA response at 10 pM (11 ± 1%), comparable to the effect of MIF-1 (18 ± 9%) at the same concentration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.